Citation Information :
El Sherif IM, Haggag AM, Abbas MH, Kamel WY. Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia. Indian J Crit Care Med 2025; 29 (1):52-58.
Aim and background: Hyperglycemia is a serious condition and associated with an increased risk of complications and mortality in both critically ill and non-critically ill people. Improvement in the glycemic level reduces the length of hospital stay, systemic infections and short- and long-term mortality. The aim was to test the effectiveness of insulin degludec vs insulin glargine and regular insulin in controlling blood sugar in patients with critical hyperglycemia.
Materials and methods: Using random control trial, the patients were randomly divided into three equal groups—group R, group G and group D. Each group included 30 patients. Group G was managed using regular insulin together with an insulin glargine. Group D was managed using regular insulin together with an insulin degludec. However, group R was managed using only regular insulin.
Results: The incidence of hypoglycemia was statistically more significant in the group of regular insulin than in groups G and group D with a p-value 0.0069. There was no statistically significant difference between the three groups regarding the frequency of hypoglycemia.
Conclusion: Ultra-long-acting insulin can effectively control random blood sugar (RBS) with a decrease in the total dose of insulin used. It is recommended that using insulin degludec is a safe and effective alternative to regular insulin for glycemic control in critically ill patients.
Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 2003;55(1):33–38. DOI: 10.1097/01.TA.00000 74434.39928.72.
Lanspa MJ, Krinsley JS, Hersh AM, Wilson EL, Holmen JR, Orme JF, et al. Percentage of time in range 70 to 139 mg/dL is associated with reduced mortality among critically ill patients receiving IV insulin infusion. Chest 2019;156 (5):878–886. DOI: 10.1016/j.chest.2019.05.016.
McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17(1):107–124. DOI: 10.1016/s0749-0704(05)70154-8.
Saberi F, Heyland D, Lam M, Rapson D, Jeejeebhoy K. Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: An observational study. JPEN J Parenter Enteral Nutr 2008;32(3):227–235. DOI: 10.1177/0148607108316195.
Fox MA, Perry MC, Liu-DeRyke X. Insulin glargine in critically ill patients: Once/day versus twice/day dosing. Pharmacotherapy 2020;40(3):186–190. DOI: 10.1002/phar.2373.
Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14(10):944–950. DOI: 10.1111/j.1463-1326.2012.01638-x.
Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29(8):2104–2114. DOI: 10.1007/s11095-012-0739-z.
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H, et al. Insulin degludec: Four times lower pharmacodynamics variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14(9):859–864. DOI: 10.1111/j.1463-1326.2012.01627-x.
Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson S, et al. Temporal relationships between severe hypogly caemia, cardiovascular outcomes and mortality. Diabetologia 2018;61(1): 58–65. DOI: 10.1007/s00125-017-4422-0.
Szabó Z, Håkanson E, Svedjeholm R. Early postoperative outcome and mediumterm survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2002;74(3):712–719. DOI: 10.1016/S0003-4975 (02)03778-5.
Anderson RE, Brismar K, Barr G, Ivert T, et al. Effects of cardiopulmonary bypass on glucose homeostasis after coronary artery bypass surgery. Eur J Cardiothorac Surg 2005;28(3):425–430. DOI: 10.1016/j.ejcts.2005.05. 025.
Bhattacharyya M, Todi SK, Majumdar A. Glargine insulin: An alternative to regular insulin for glycemic control in critically ill patients. Crit Care 2007;11(Suppl 2):P131. DOI: 10.1186/cc5291.
Nader ND, Hamishehkar H, Naghizadeh A, Shadvar K, Iranpour A, Sanaie S, et al. Effect of adding insulin glargine on glycemic control in critically ill patients admitted to intensive care units: A prospective randomized controlled study. Diabetes Metab Syndr Obes 2020;13:671–678. DOI: 10.2147/DMSO.S240645.
Van den Berghe G, Wilmer A, Hermans G, Meersseman, W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354(5):449–461. DOI: 10.1056/NEJMoa052521.
Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 2004;10 Suppl 2:46–52. DOI: 10.4158/EP.10.S2.46.
Stapleton RD, Heyland DK. Glycemic control in critically ill adult and pediatric patients. Available at UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on 02 August, 2024).
Oya J, Nakagami T, Hasegawa Y, Katamine A, Kondo Y, Babazono T, et al. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes. J Diabetes Investig 2021;12(11):1983–1991. DOI: 10.1111/jdi.13559.
Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab 2017;19(7):1032–1039. DOI: 10.1111/dom.12938.
